Strong Inhibitors of CYP3A4/5 Enzymes: Ketoconazole significantly increased saxagliptin exposure. Similar significant increases in plasma concentrations of saxagliptin are anticipated with other strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin). The dose of ONGLYZA should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor [see Dosage & Administration and Pharmacology under Actions].
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Manage Account
Change Password
Sign Out
